• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.

作者信息

Landmesser Ulf, Chapman M John, Stock Jane K, Amarenco Pierre, Belch Jill J F, Borén Jan, Farnier Michel, Ference Brian A, Gielen Stephan, Graham Ian, Grobbee Diederick E, Hovingh G Kees, Lüscher Thomas F, Piepoli Massimo F, Ray Kausik K, Stroes Erik S, Wiklund Olov, Windecker Stephan, Zamorano Jose Luis, Pinto Fausto, Tokgözoglu Lale, Bax Jeroen J, Catapano Alberico L

机构信息

Department of Cardiology, Charite Universitätsmedizin Berlin, Berlin Institute of Health (BIH), German Center of Cardiovascular Research (DZHK), Hindenburgdamm 30, 12203 Berlin, Germany.

National Institute for Health and Medical Research (INSERM), University of Pierre and Marie Curie, Pitié-Salpêtrière Hospital, Paris, France.

出版信息

Eur Heart J. 2018 Apr 7;39(14):1131-1143. doi: 10.1093/eurheartj/ehx549.

DOI:10.1093/eurheartj/ehx549
PMID:29045644
Abstract
摘要

相似文献

1
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.欧洲心脏病学会/欧洲动脉粥样硬化学会前蛋白转化酶枯草溶菌素9型抑制剂在动脉粥样硬化性心血管疾病患者或家族性高胆固醇血症患者中应用的实用临床指南工作组2017年更新版
Eur Heart J. 2018 Apr 7;39(14):1131-1143. doi: 10.1093/eurheartj/ehx549.
2
CardioPulse: The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitors.《心脏脉搏》：欧洲药品管理局对前蛋白转化酶枯草溶菌素/克新9型抑制剂的批准
Eur Heart J. 2016 Feb 7;37(6):502-3. doi: 10.1093/eurheartj/ehv685.
3
Proprotein convertase subtilisin/kexin type 9 inhibitors: New insights into cardiovascular atherosclerotic pathophysiology with therapeutic implications.前蛋白转化酶枯草杆菌蛋白酶/克新9型抑制剂：对心血管动脉粥样硬化病理生理学的新见解及其治疗意义。
Arch Cardiovasc Dis. 2019 Aug-Sep;112(8-9):455-458. doi: 10.1016/j.acvd.2019.06.003. Epub 2019 Sep 5.
4
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.前蛋白转化酶枯草溶菌素/kexin 9型（PCSK9）抑制剂。一种用于治疗高胆固醇血症的新型药物类别。
Endocrinol Diabetes Nutr. 2017 Aug-Sep;64(7):341-344. doi: 10.1016/j.endinu.2017.04.005. Epub 2017 Jun 3.
5
Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor.诊断对前蛋白转化酶枯草杆菌蛋白酶/克新9型抑制剂的耐药性。
Ann Intern Med. 2018 Mar 6;168(5):376-379. doi: 10.7326/M17-2485. Epub 2017 Nov 28.
6
Inhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia.前蛋白转化酶枯草溶菌素/kexin 9型抑制剂在高胆固醇血症治疗中的应用
Endocrinol Nutr. 2016 Jun-Jul;63(6):255-7. doi: 10.1016/j.endonu.2016.02.002. Epub 2016 Apr 1.
7
[PCSK-9 inhibitors, effects on LDL-C and future implications: What you should know].[前蛋白转化酶枯草溶菌素9抑制剂对低密度脂蛋白胆固醇的影响及未来意义：你应该了解的内容]
Hipertens Riesgo Vasc. 2017 Oct-Dec;34(4):176-183. doi: 10.1016/j.hipert.2017.06.001. Epub 2017 Jul 12.
8
Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.依洛尤单抗联合常规药物治疗，伴或不伴血浆分离术，用于治疗纯合子家族性高胆固醇血症患者：开放标签 TAUSSIG 研究的中期亚组分析。
Lancet Diabetes Endocrinol. 2017 Apr;5(4):280-290. doi: 10.1016/S2213-8587(17)30044-X. Epub 2017 Feb 16.
9
Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.临床动脉粥样硬化性心血管疾病或杂合子家族性高胆固醇血症合格患者中前蛋白转化酶枯草溶菌素9型抑制剂的处方模式
Am J Cardiol. 2018 May 15;121(10):1155-1161. doi: 10.1016/j.amjcard.2018.02.002. Epub 2018 Feb 12.
10
Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia.家族性高胆固醇血症患者的血浆前蛋白转化酶枯草溶菌素/凝血酶 9 浓度与复发性心血管事件。
Eur J Prev Cardiol. 2021 Apr 23;28(3):272-279. doi: 10.1177/2047487319880985. Epub 2019 Oct 11.

引用本文的文献

1
PCSK9 inhibitors in real life-Cardiometabolic risk management in dyslipidemic patients in Vienna.现实生活中的前蛋白转化酶枯草溶菌素9抑制剂——维也纳血脂异常患者的心脏代谢风险管理
Wien Klin Wochenschr. 2025 May;137(9-10):307-313. doi: 10.1007/s00508-024-02402-9. Epub 2024 Aug 13.
2
Apolipoprotein B - An ideal biomarker for atherosclerosis?载脂蛋白 B - 动脉粥样硬化的理想生物标志物？
Indian Heart J. 2024 Mar;76 Suppl 1(Suppl 1):S121-S129. doi: 10.1016/j.ihj.2023.12.001. Epub 2024 Apr 8.
3
Failure of lipid control by PCSK9 inhibitors in compound heterozygous familial hypercholesterolemia complicated with premature myocardial infarction: A case report.
前蛋白转化酶枯草溶菌素9抑制剂对复合杂合子家族性高胆固醇血症合并早发心肌梗死患者血脂控制失效：一例报告
Clin Case Rep. 2024 Mar 14;12(3):e8498. doi: 10.1002/ccr3.8498. eCollection 2024 Mar.
4
Approach to the Patient With a Suboptimal Statin Response: Causes and Algorithm for Clinical Management.他汀类药物反应不佳患者的处理方法：临床管理的原因和算法。
J Clin Endocrinol Metab. 2023 Aug 18;108(9):2424-2434. doi: 10.1210/clinem/dgad153.
5
How Can Implementation Science Improve the Care of Familial Hypercholesterolaemia?如何利用实施科学改善家族性高胆固醇血症的治疗？
Curr Atheroscler Rep. 2023 Apr;25(4):133-143. doi: 10.1007/s11883-023-01090-6. Epub 2023 Feb 20.
6
Real-World Use of Alirocumab: Experience from a Large Healthcare Provider.阿利西尤单抗的真实世界应用：来自大型医疗服务机构的经验
J Clin Med. 2023 Jan 30;12(3):1084. doi: 10.3390/jcm12031084.
7
Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat.阿利西尤单抗和依洛尤单抗对全因死亡率和主要心血管事件的影响：一项聚焦于治疗所需人数的荟萃分析。
Front Cardiovasc Med. 2022 Dec 2;9:1016802. doi: 10.3389/fcvm.2022.1016802. eCollection 2022.
8
2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea.《2022年韩国家族性高胆固醇血症管理共识声明》
J Lipid Atheroscler. 2022 Sep;11(3):213-228. doi: 10.12997/jla.2022.11.3.213. Epub 2022 Jul 7.
9
Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE).阿利西尤单抗治疗动脉粥样硬化性心血管疾病或杂合子家族性高胆固醇血症患者难治性高胆固醇血症的优化治疗（OPTIMIZE）。
Front Cardiovasc Med. 2022 Jul 15;9:953040. doi: 10.3389/fcvm.2022.953040. eCollection 2022.
10
2022 Consensus statement on the management of familial hypercholesterolemia in Korea.2022 年韩国家族性高胆固醇血症管理共识声明。
Korean J Intern Med. 2022 Sep;37(5):931-944. doi: 10.3904/kjim.2022.121. Epub 2022 Jul 27.